<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Allergic fungal rhinosinusitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Allergic fungal rhinosinusitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Allergic fungal rhinosinusitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rodney J Schlosser, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Corren, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 27, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H346048597"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Allergic fungal rhinosinusitis (AFRS) is a distinct type of chronic rhinosinusitis (CRS), accounting for between 5 and 10 percent of all CRS cases. AFRS is believed to result from chronic, intense allergic inflammation directed against colonizing fungi. Patients with AFRS are immunocompetent and show evidence of allergy to one or more fungi. Definitive diagnosis is usually confirmed after sinus surgery. Successful treatment involves a combination of surgical and medical management.</p><p>The pathogenesis, clinical manifestations, diagnosis, differential diagnosis, and management of AFRS are reviewed here. More general topics about CRS are found separately. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H346048603"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>AFRS is defined as a specific subtype of chronic rhinosinusitis (CRS). All forms of CRS are defined as inflammatory conditions involving the paranasal sinuses and linings of the nasal passages that last 12 weeks or longer. The diagnosis of all forms of CRS requires objective evidence of mucosal inflammation. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Definition'</a>.)</p><p>AFRS is a distinct subtype of CRS that arises as a result of a localized allergic reaction to noninvasive fungal growth in areas of compromised mucus drainage [<a href="#rid1">1,2</a>]. AFRS is defined as an intense, localized allergic/eosinophilic inflammatory sinus disease that results in the accumulation of eosinophilic (allergic) mucin (a thick, tenacious eosinophilic secretion that contains fungal hyphae), intense eosinophilic inflammation, and characteristic radiographic findings. The diagnostic criteria for AFRS require:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of CRS with nasal polyposis (NP), unless the patient has undergone surgery or aggressive medical therapy with systemic glucocorticoids to remove or shrink the polyps.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of eosinophilic mucin (with pathology showing fungal hyphae and degranulating eosinophils).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of immunoglobulin (Ig)E-mediated allergy to fungus (documented either by skin testing or in vitro IgE immunoassays).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No</strong> evidence of invasive fungal disease, diabetes mellitus, or immunodeficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Characteristic radiographic findings.</p><p></p><p>Diagnosis is discussed in more detail below. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H1797180589"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathophysiology of AFRS is most consistent with chronic, intense T helper type 2 (Th2) allergic inflammation directed against colonizing fungi. The sinuses become filled with thick, inspissated mucus that is dense with degranulating eosinophils [<a href="#rid3">3</a>].</p><p>Key steps in the pathogenesis are outlined below, although this sequence of events is largely theoretical (modified from [<a href="#rid4">4</a>]):</p><p class="bulletIndent1"><span class="glyph">●</span>Fungal spores become trapped in nasal or sinus mucus. This is known to occur in healthy subjects, depending on geographic and climatic conditions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The host becomes sensitized to fungal antigens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some of the fungal spores germinate into hyphae. The hyphae provide the local antigenic stimulus for the allergic response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The large local load of fungal antigen elicits a localized Th2-allergic immune response. This likely explains the localization of disease to one or more sinuses (AFRS is often a unilateral process).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic allergic inflammation results in local fungal-specific IgE production, mast cell degranulation, and late-phase allergic inflammation, with an influx of large numbers of eosinophils.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The eosinophils attack the fungal hyphae, degranulate and release inflammatory mediators, cytokines, and growth factors that amplify the inflammatory process, and may contribute to airway remodeling, nasal polyp formation, and possibly to bony demineralization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The sinonasal mucosa becomes damaged, which facilitates bacterial penetration of the mucosa, leading to bacterial infection, biofilm formation, and further perpetuation of the inflammatory process.</p><p></p><p>The Th2-derived cytokines, interleukin-5 (IL-5) and interleukin-13 (IL-13), are likely involved in the local eosinophil accumulation and subsequent eosinophil-mediated attack of fungal hyphae in mucus. In an in vitro study, peripheral blood lymphocytes from patients with AFRS produced greater amounts of IL-5 when stimulated by fungal antigens from <em>Alternaria</em> and <em>Cladosporium</em>, compared with lymphocytes from healthy control subjects [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H19356648"><span class="h2">The role of allergy</span><span class="headingEndMark"> — </span>Patients with AFRS are, by definition, allergic to one or more fungi, as determined by skin testing or in vitro testing for fungal-specific IgE. However, one study found that AFRS patients were not distinguishable from patients with allergic rhinitis and fungal allergy in the following parameters: total serum IgE, serum levels of <em>Alternaria alternata</em>-specific or <em>Aspergillus fumigatus</em>-specific IgE, IgG, or IgA levels, or the percent of fungal-specific serum IgE relative to total serum IgE measurements [<a href="#rid6">6</a>]. Furthermore, the prevalence of fungal allergy to <em>A. alternata</em> or <em>A. fumigatus</em> in AFRS and AFRS-like patients was no different from that observed in allergic rhinitis with fungal allergy. These findings suggest that allergy to fungus by itself is not sufficient to explain the pathophysiology of AFRS. The other factors that determine why one patient with allergy to fungus develops AFRS while another has uncomplicated allergic rhinitis are undefined.</p><p class="headingAnchor" id="H1797180691"><span class="h2">Fungi implicated in AFRS</span><span class="headingEndMark"> — </span>The most common fungi reported to cause AFRS are <em>Bipolaris</em>, <em>Curvularia</em>, <em>Aspergillus</em>, <em>Exserohilum</em>, and <em>Drechslera</em> species, with a wide variety of other fungi implicated in case reports [<a href="#rid7">7,8</a>]. Newer culture techniques and identification of the fungal microbiome will undoubtedly improve our understanding of fungi and their role in AFRS [<a href="#rid9">9,10</a>]. When AFRS was first recognized in the 1970s, it was believed to represent an upper airway manifestation of allergic bronchopulmonary aspergillosis (ABPA) [<a href="#rid11">11</a>]. However, the co-occurrence of these two conditions is infrequent, and <em>Aspergillus</em> is just one of the many fungi that cause AFRS, although it may be a more common culprit in other parts of the world [<a href="#rid7">7,12</a>].</p><p>The fungi that most commonly cause AFRS belong to the "dematiaceous" or "melanized" group of fungi, sometimes called "dark" fungi [<a href="#rid13">13</a>]. The reasons for this are not known, and nondematiaceous fungi can also cause AFRS. Dematiaceous fungi have brown pigmented hyphae that are often discernible in tissue specimens without the use of staining procedures [<a href="#rid13">13</a>]. However, the presence of melanin alone is insufficient for inclusion in this group, as some amount of melanin is also present in nondematiaceous fungi. The vast majority of dematiaceous fungi are of no clinical significance, although some cause opportunistic infections (local or systemic) in immunocompromised hosts [<a href="#rid14">14</a>]. In the absence of dark pigment in the cell wall of hyphae, a special stain called Fontana-Masson (FM) can be used to observe melanin pigment in the fungal cell walls. Many <em>Aspergillus</em> species, which are nondematiaceous, and some zygomycetes also stain positively with FM, whereas other fungi showed either weak intensity or no staining [<a href="#rid15">15</a>]. The stains typically used in diagnosis are discussed below. (See <a class="local">'Detection of fungi'</a> below.)</p><p class="headingAnchor" id="H1797180749"><span class="h2">Controversial issues</span><span class="headingEndMark"> — </span>Fungi have been proposed to play a much broader role in the pathogenesis of other forms of chronic rhinosinusitis (CRS), namely CRS without nasal polyposis (NP) and CRS with NP [<a href="#rid9">9,16-18</a>]. Some studies have reported that fungi are present in the mucus of the vast majority of patients with CRS and that peripheral blood T lymphocytes from CRS patients produce eosinophil-promoting cytokines, including IL-5 and IL-13, when exposed in vitro to certain fungi, most notably <em>Alternaria</em> [<a href="#rid16">16</a>]. However, this theory is controversial, and other studies have reported that fungal hyphae are not universally found in the mucus of non-AFRS CRS cases [<a href="#rid19">19</a>]. In addition, other studies failed to confirm that fungi elicit strong immunologic responses in CRS patients [<a href="#rid20">20,21</a>].</p><p class="headingAnchor" id="H13977677"><span class="h2">Bacterial coinfection</span><span class="headingEndMark"> — </span>Although AFRS is not caused by bacterial infection, it has been observed that bacterial coinfection in AFRS cases is not uncommon. Indeed, a higher rate of mucosal colonization with enterotoxin-producing <em>Staphylococcus aureus</em> has been reported in AFRS compared with non-AFRS CRS with NP, and a pathologic role for <em>S. aureus</em> has been proposed in AFRS [<a href="#rid22">22,23</a>]. It is possible that such enterotoxins contribute to the Th2 microenvironment in these patients. The microbiology and antimicrobial therapy of CRS are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3412.html" rel="external">"Microbiology and antibiotic management of chronic rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H256177493"><span class="h1">EPIDEMIOLOGY AND POSSIBLE RISK FACTORS</span><span class="headingEndMark"> — </span>AFRS occurs worldwide, although most published reports are from the southern United States. In a systematic review of studies from around the world, the prevalence of AFRS among patients with chronic rhinosinusitis with nasal polyposis (CRS with NP) in 35 cities across 5 continents was approximately 8 percent, with a range of 0.2 to 27 percent [<a href="#rid24">24</a>]. Climactic factors that were associated with a higher prevalence of AFRS were hotter, less humid, and less windy climates. No correlations were found with presence of water bodies, forests, average rainfall, or altitude. </p><p>The majority of cases of AFRS have been reported in the southern United States, specifically along the Mississippi River basin [<a href="#rid25">25</a>]. This distribution has not been definitively tied to specific geographic conditions, such as differences in ambient mold spore counts, although it unlikely to be simply a selection bias resulting from the research interests of investigators from these areas. Another important epidemiologic feature of AFRS in the United States is a higher prevalence in younger patients, African Americans, uninsured or Medicaid patients, and patients residing in counties with higher poverty rates [<a href="#rid26">26</a>]. It is possible that lower socioeconomic status may play a role through delayed access to care, differences in quality of care, or poor housing quality, although this association requires further study [<a href="#rid26">26,27</a>]. A study of mold exposure in the homes of patients with AFRS compared with those with CRS w NP did not reveal significant differences, despite the presence of socioeconomic differences [<a href="#rid28">28</a>]. </p><p class="headingAnchor" id="H346048615"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H346048622"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>The symptoms of AFRS are similar to chronic rhinosinusitis with nasal polyposis (CRS with NP), since AFRS patients uniformly have NP. Early disease may present with innocuous-sounding nasal congestion or obstruction, anosmia, and postnasal drainage. Fever is uncommon. Patients may report that semisolid nasal crusts or rubbery globs of dark-colored mucus are periodically expelled from the nose [<a href="#rid11">11</a>].</p><p>The four cardinal symptoms of CRS are:</p><p class="bulletIndent1"><span class="glyph">●</span>Anterior and/or posterior nasal mucopurulent drainage</p><p class="bulletIndent1"><span class="glyph">●</span>Nasal obstruction, nasal blockage, congestion</p><p class="bulletIndent1"><span class="glyph">●</span>Facial pain, pressure, and/or fullness</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction or loss of sense of smell</p><p></p><p>At least two of the four cardinal symptoms of CRS are required for the diagnosis of AFRS, similar to other forms of CRS [<a href="#rid29">29</a>]. The cardinal CRS symptoms and the diagnosis of CRS are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'Signs and symptoms'</a>.)</p><p>Some patients may have multiple symptoms, including anosmia, rhinorrhea, and cough. However, none of these are specific for AFRS. Occasionally, AFRS presents dramatically with complete nasal obstruction, gross facial asymmetry, and/or visual changes [<a href="#rid29">29,30</a>]. Children present with proptosis more commonly than adults [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H346048628"><span class="h2">Warning signs and complications</span><span class="headingEndMark"> — </span>Moderate and severe AFRS can lead to bony expansion and bony erosion, with extension to extrasinus areas, such as the orbit, skin, and brain. This happens more with AFRS than with other forms of CRS. The following symptoms may develop as a result of bony expansion or erosion: double or reduced vision, proptosis, dramatic periorbital edema, ophthalmoplegia, facial dysmorphia, other focal neurologic signs, severe headache, meningeal signs, or significant or recurrent epistaxis [<a href="#rid7">7,32-34</a>]. Urgent referral to an otolaryngologist/head and neck surgeon is indicated in the presence of these symptoms, even if they have developed gradually. (See <a class="local">'Findings on imaging studies'</a> below.)</p><p class="headingAnchor" id="H346048634"><span class="h2">Impact on quality of life</span><span class="headingEndMark"> — </span>The impact of AFRS upon quality of life is similar to other forms of CRS, and AFRS has similar clinical outcomes [<a href="#rid35">35,36</a>]. One study documented that patients with CRS had significantly lower quality of life scores for social functioning as well as physical and overall health, compared with the general population, with decrements similar to chronic lung or heart illnesses [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H346048694"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The evaluation of AFRS is similar to that of chronic rhinosinusitis (CRS). It involves a clinical history, objective documentation of mucosal disease (with sinus imaging or nasal endoscopy), allergy evaluation, consideration of immunologic defects and infectious complications, and in most cases, endoscopic sinus surgery (ESS). These components of diagnosis, as they apply to all forms of CRS, are summarized separately. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1797181280"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Patients with AFRS may have elevations of total serum IgE and peripheral blood eosinophilia, although these abnormalities are not required for the diagnosis. In one study of 99 patients with either AFRS or CRS, total IgE in patients with AFRS was significantly higher than in those with CRS (mean levels, 1146 versus 247 kU/L) [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H19356891"><span class="h2">Allergy evaluation</span><span class="headingEndMark"> — </span>Patients with AFRS must demonstrate IgE-mediated allergy to fungus either by skin testing or in vitro immunoassays. Both epicutaneous (ie, prick/puncture) and intradermal test results are relevant [<a href="#rid3">3</a>]. Most patients with AFRS show allergy to more than one fungus, although sensitization to multiple fungi is not required for the diagnosis. Skin testing for other perennial allergens (dust mite, cockroach, and animal danders) is also recommended, as these are potentially relevant to any patient with CRS.</p><p class="headingAnchor" id="H19356708"><span class="h2">Findings on imaging studies</span></p><p class="headingAnchor" id="H1797181314"><span class="h3">Sinus CT</span><span class="headingEndMark"> — </span>Any patient with CRS who has failed conservative treatment, who is being considered for sinus surgery, or who is suspected of having AFRS based on physical examination findings should have a computed tomography (CT) study of the paranasal sinuses. Characteristic findings are usually present despite previous medical therapy, including both antibiotics and oral glucocorticoids.</p><p>Sinus CT usually reveals nasal polyposis (NP) with opacification of one or more sinuses. In the majority of cases, multiple sinuses are involved [<a href="#rid39">39,40</a>]. There may be unilateral or bilateral sinus involvement in AFRS, with up to one-half of cases presenting with unilateral disease. AFRS is an important consideration in the evaluation of a child with a unilateral sinus disease or unilateral nasal mass [<a href="#rid30">30</a>]. Similar to CRS with NP, sinus opacification is typically found in the absence of facial pain, pressure, and headaches.</p><p>A characteristic CT finding in AFRS is differential densities (hyperattenuated areas) within the opacified sinuses, which indicates the presence of dense accumulations of eosinophilic mucin in those sinuses  (<a class="graphic graphic_diagnosticimage graphicRef77812" href="/z/d/graphic/77812.html" rel="external">image 1</a>). Local pressure on the bony walls of the sinus cavity may result in expansion of this sinus cavity and bony demineralization over time. True bone erosion is less common, occurring in 20 percent of cases [<a href="#rid41">41</a>].</p><p>Both mucus accumulation and mucosal thickening contribute significantly to sinus opacification and are difficult to differentiate with sinus CT imaging. The main distinguishing features of AFRS on sinus CT include:</p><p class="bulletIndent1"><span class="glyph">●</span>One or more opacified sinuses with foci of increased density ("hyperdensities") corresponding to the presence of eosinophilic mucin – Eosinophilic mucin has areas of high protein content and low water content that give rise to characteristic hyperdense appearance on sinus CT  (<a class="graphic graphic_diagnosticimage graphicRef102290" href="/z/d/graphic/102290.html" rel="external">image 2</a>). These same areas appear "hypointense" on T2-weighted magnetic resonance images (MRIs). Although this is considered a pathognomonic feature of AFRS, it actually signifies the presence of "allergic mucin," which can be found in other disorders. (See <a class="local">'Eosinophilic mucin rhinosinusitis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bony demineralization of the sinus wall resulting in sinus expansion</strong> – Occasionally, sinus cavity opacification in AFRS may be associated with local pressure effects on bone. Bony demineralization of the sinus wall may ensue, resulting in expansion of the sinus and possibly mucocele formation. A study of this process concluded that bony demineralization was caused by intense, local mucosal allergic inflammation adjacent to areas of eosinophilic mucin accumulation [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>True bone erosion</strong> – Expansile bone erosion occurs in 20 to 30 percent of AFRS cases in most series and is far more common in AFRS than in other forms of CRS  (<a class="graphic graphic_diagnosticimage graphicRef102291" href="/z/d/graphic/102291.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef102292" href="/z/d/graphic/102292.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef102293" href="/z/d/graphic/102293.html" rel="external">image 5</a>) [<a href="#rid40">40,41,43-46</a>]. Males appear to be at higher risk [<a href="#rid47">47</a>]. When bone destruction is present, it is imperative to rule out invasive fungal sinusitis, although the bony destruction seen with invasive fungal sinusitis is not typically expansile in nature. Nearly any malignancy can also cause bone destruction, and if there is concern, biopsy and clinical correlation should be considered. (See <a class="local">'Acute or chronic invasive fungal sinusitis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nasal cavity expansion</strong> – In addition to erosion and expansion of the sinus bone, AFRS can also expand within the nasal cavity. While this can be evident upon CT, it can also lead to widening of the piriform aperture and hypertelorism that is visible externally.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expansion of soft tissue disease into the orbit, soft tissue of the face, or brain</strong> – In some cases, the expansion of soft tissue disease results in gross facial dysmorphia.</p><p></p><p class="headingAnchor" id="H1797181632"><span class="h3">Sinus MRI</span><span class="headingEndMark"> — </span>The combination of CT and magnetic resonance imaging (MRI) techniques can provide a more precise differentiation of mucus accumulation and mucosal thickening within sinus cavities [<a href="#rid31">31</a>]. This is particularly useful for distinguishing the eosinophilic mucin of AFRS from other material in an opacified sinus (such as infected fluid or trapped secretions in a mucocele). Eosinophilic mucin produces characteristic hyperdensities on CT, which appear as hypoattenuated (or hypointense) areas on T2-weighted MRIs  (<a class="graphic graphic_diagnosticimage graphicRef102293" href="/z/d/graphic/102293.html" rel="external">image 5</a>) [<a href="#rid31">31</a>]. MRI is also more sensitive in differentiating inflammatory conditions from neoplastic processes and in detecting subtle or obvious intracranial spread of disease [<a href="#rid31">31</a>]. For these reasons, it is sometimes advisable to obtain both a CT and MRI before performing sinus surgery.</p><p>The decreased signal intensity on T1-weighted MRIs and the very decreased signal intensity on T2-weighted MRIs were previously thought to be due to calcium, iron, and manganese within the mucin [<a href="#rid48">48</a>]. However, it is believed that the presence of inspissated mucus within the sinus cavity or along the crevices of polyps results in a markedly hypointense T2-weighted signal [<a href="#rid31">31,40</a>]. Therefore, hyperdensities on sinus CT scan are most consistent with the presence of eosinophilic mucin and suggestive but not actually pathognomonic of AFRS [<a href="#rid49">49,50</a>].</p><p class="headingAnchor" id="H1797181758"><span class="h2">Histologic findings</span><span class="headingEndMark"> — </span>Eosinophilic mucin is generally identified at the time of surgery, and its presence is required for the diagnosis.</p><p class="headingAnchor" id="H347023235"><span class="h3">Eosinophilic mucin</span><span class="headingEndMark"> — </span>Eosinophilic mucin is thick, inspissated material that occupies one or more sinuses in AFRS and ranges in color from light tan to brown to dark green  (<a class="graphic graphic_picture graphicRef67108" href="/z/d/graphic/67108.html" rel="external">picture 1</a>) [<a href="#rid51">51</a>]. It contains sheets of degranulating eosinophils and Charcot-Leyden crystals [<a href="#rid11">11</a>]. Eosinophilic mucin is not specific to AFRS, as it can also be seen in the other subtypes of CRS [<a href="#rid52">52</a>]. However, in AFRS, the eosinophilic mucin contains fungal hyphae demonstrable by staining or fungal culture, as discussed in the next section.</p><p class="headingAnchor" id="H364301722"><span class="h3">Detection of fungi</span><span class="headingEndMark"> — </span>The eosinophilic mucin in AFRS contains fungal hyphae, which is indicative of fungal colonization. To make a diagnosis of AFRS, it is necessary to confirm the presence of fungi in the eosinophilic mucin, either by a positive fungal stain or a positive fungal culture. By contrast, in invasive fungal sinusitis, fungal hyphae can be shown histologically to penetrate the underlying mucosa. Therefore, to exclude invasive fungal sinusitis, pathologic examination must confirm that there are no fungal hyphae invading tissue or bone.</p><p class="bulletIndent1"><span class="glyph">●</span>Documentation of fungal hyphae in mucus samples requires specific staining, such as Grocott or Gomori methenamine silver (GMS) stain, which stain fungal hyphae black or dark brown. Silver-based stains have high specificity but low sensitivity. The insensitivity of this stain for detecting fungi has led to a proposed modification involving predigestion of the mucin with trypsin [<a href="#rid53">53</a>]. Using this technique, one group identified fungal hyphae in 91 percent of CRS mucus samples, whereas fungal hyphae were identified in only 27 percent of specimens using conventional GMS staining [<a href="#rid53">53</a>]. We believe this modified staining technique deserves consideration for more widespread use by pathologists, although it has not been widely adopted. (See  <a class="medical medical_review" href="/z/d/html/2452.html" rel="external">"Fungal rhinosinusitis", section on 'Invasive fungal sinusitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Fontana-Masson (FM) stain may increase the sensitivity for identifying dematiaceous fungi in allergic mucin when used in conjunction with standard GMS staining, although confirmation of fungal species still requires fungal culture or a polymerase chain reaction (PCR)-based assay [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fungal cultures are typically performed in parallel with fungal staining of eosinophilic mucin. However, routine fungal cultures have a low yield, even in cases of AFRS. Methods to increase the yield of fungal cultures of CRS patients of all types were described by investigators from the Mayo Clinic (the "Mayo technique"). This technique involves pretreatment of the mucus sample with a 50/50 mixture of dithiothreitol (DTT 1.055 mg/mL) for 15 minutes at room temperature, centrifugation of the sample at 3000 RPM for 10 minutes, homogenization of the sample by vortexing, and inoculation of the sample on three different culture media, each in duplicate: Sabouraud glucose agar, malt extract agar, and Czapek-Dox agar. One set of cultures is incubated at 20°C (68°F) and the other set at 30°C (86°F) for up to six weeks in laminar flow box [<a href="#rid9">9</a>]. Confirmatory results of fungal cultures using this technique were reported in a study of CRS patients from Austria [<a href="#rid17">17</a>]. Finally, a study of AFRS patients confirmed an increased yield of fungal cultures using a modification of this technique from 16 to 64 percent [<a href="#rid54">54</a>]. It should be acknowledged that there is no consensus on the optimal methods for culturing fungi from sinus specimens, and the "Mayo technique" has yet to be widely adopted into clinical practice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study treated specimens with dembrexine hydrochloride (a phenolic benzylamine mucolytic agent) and <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">chloramphenicol</a>, plating on Sabouraud, CHROMagar/Candida, Mycosel, and Niger seed agar plates and incubating at 30°C (86°F) (or 37°C [98.6°F]) for up to one month [<a href="#rid55">55</a>]. These various methods of fungal staining and fungal culture are not widely adopted in clinical practice but serve to underscore that there is a need for more sensitive techniques for the diagnosis of AFRS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A rapid in-situ hybridization diagnostic probe for dematiaceous fungi has been reported but is not widely used [<a href="#rid56">56</a>]. This probe may be useful in confirming cases of AFRS by examination of mucus samples. However, a positive probe test can also be seen in other conditions, such as a fungus ball or invasive fungal sinusitis.</p><p></p><p class="headingAnchor" id="H1797180195"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnostic criteria for AFRS have been proposed by two groups of investigators [<a href="#rid39">39,57</a>]. Subsequently, definitions for use in patient care were published [<a href="#rid29">29</a>].</p><p>The diagnosis of AFRS can be made when <strong>all</strong> of the following criteria are satisfied:</p><p class="bulletIndent1"><span class="glyph">●</span>The subject has symptoms of chronic rhinosinusitis (CRS) (anterior and/or posterior nasal mucopurulent drainage; nasal obstruction, blockage or congestion; facial pain, pressure, and/or fullness and reduction or loss of sense of smell), although it has been observed that the clinical presentation in AFRS patients can be subtle despite evidence of extensive sinus disease on imaging studies [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of eosinophilic mucin in one or more sinus cavities confirmed during sinus surgery. (See <a class="local">'Eosinophilic mucin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noninvasive</strong> fungal hyphae are demonstrated in the eosinophilic mucin (note that it is essential to confirm histologically that the fungal hyphae do not invade the mucosa in order to exclude invasive fungal sinusitis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient is immunocompetent with no evidence of uncontrolled diabetes, drug-induced immunosuppression, unexplained weight loss, or impaired cellular immunity (ie, abnormal T cell subsets, history of excessive or unusual infections outside of the sinuses).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Characteristic computed tomography (CT) findings are present with differential densities on soft tissue windowing. (See <a class="local">'Findings on imaging studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fungus-specific IgE is demonstrated. (See <a class="local">'Allergy evaluation'</a> above.)</p><p></p><p class="headingAnchor" id="H346048700"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of AFRS includes the following disorders.</p><p class="headingAnchor" id="H346048706"><span class="h2">Allergic rhinitis with fungal allergy</span><span class="headingEndMark"> — </span>Fungal allergy is present in 2.7 to 44 percent of patients with allergic rhinitis, depending on geographic area and which types of fungi were included in the survey [<a href="#rid58">58</a>]. However, the prevalence of fungal allergy is likely underestimated owing to the multitude of different types of ambient fungal spores, many of which are not included in fungal allergy testing panels. An example is the basidiomycetes species, which is not widely included in allergy skin testing panels [<a href="#rid59">59</a>]. Patients with uncomplicated allergic rhinitis can be easily distinguished from AFRS because they do not have nasal polyposis (NP) or symptoms suggestive of chronic rhinosinusitis (CRS). (See  <a class="medical medical_review" href="/z/d/html/7525.html" rel="external">"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis"</a>.)</p><p class="headingAnchor" id="H346048712"><span class="h2">Chronic rhinosinusitis with fungal allergy</span><span class="headingEndMark"> — </span>Fungal allergy is found in about 20 percent of CRS cases overall. Incidental fungal colonization may occasionally be found in sinus mucus by stain or culture in the absence of eosinophilic mucin and may vary depending upon the sensitivity of culture technique. Patients with CRS with NP may present similarly to those with AFRS. However, CRS (with or without NP) is distinguished from AFRS by the absence of eosinophilic mucin containing fungal hyphae (as demonstrated by fungal staining or culture) and the absence of computed tomography (CT) findings suggestive of AFRS. In addition, CRS with NP is almost always bilateral. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p class="headingAnchor" id="H346048718"><span class="h2">Fungus ball</span><span class="headingEndMark"> — </span>Fungal balls occur in patients with normal immune function and represent a noninvasive collection of mucus and fungus <strong>un</strong>accompanied by an immunologic response [<a href="#rid60">60</a>]. Type I hypersensitivity to fungi may be present, although it is incidental and does not play a role in the pathophysiology. Consequently, there is no eosinophilic inflammation and no eosinophilic mucin. The fungal species found in fungus balls and AFRS can be similar. CT findings of fungus balls can also show differential densities, and magnetic resonance imaging (MRI) will have decreased signal intensity, but fungus balls less commonly cause bony erosion/expansion. In addition, fungus balls are usually limited to single sinuses (most often the maxillary and sphenoid)  (<a class="graphic graphic_diagnosticimage graphicRef102294" href="/z/d/graphic/102294.html" rel="external">image 6</a>). (See  <a class="medical medical_review" href="/z/d/html/2452.html" rel="external">"Fungal rhinosinusitis", section on 'Fungus balls'</a>.)</p><p class="headingAnchor" id="H346048724"><span class="h2">Acute or chronic invasive fungal sinusitis</span><span class="headingEndMark"> — </span>This is the most important disease to distinguish from AFRS because invasive fungal sinusitis is potentially lethal, and delays in the diagnosis can be catastrophic. In acute or chronic invasive fungal sinusitis, fungal hyphae are located within the sinus mucosa, submucosa, blood vessels, or bone [<a href="#rid61">61</a>]. Acute invasive fungal sinusitis generally occurs only in diabetics or immunocompromised hosts [<a href="#rid62">62-64</a>]. A study of 179 patients with the condition found that 70 percent had diabetes and 26 percent had underlying diseases, such as leukemia, renal disease, or transplant-related immunosuppression [<a href="#rid62">62</a>]. Chronic forms of invasive fungal sinusitis also occur predominantly in immunocompromised hosts, and most reports have been from outside of the United States [<a href="#rid63">63,64</a>]. (See  <a class="medical medical_review" href="/z/d/html/2452.html" rel="external">"Fungal rhinosinusitis", section on 'Invasive fungal sinusitis'</a>.)</p><p>There may be some radiographic features that distinguish invasive fungal sinusitis from AFRS. In a prospective series of 29 patients with these disorders, AFRS cases were more likely to show heterogenous hyperdensities on CT, corresponding isointense/hypointense or signal void areas on T1-weighted and T2-weighted MRIs, sinus expansion, extensive bone erosion, lack of contrast enhancement, multiple sinus involvement, and predominantly intrasinus rather than extrasinus disease [<a href="#rid65">65</a>]. In contrast, imaging in patients with invasive fungal sinusitis was more likely to show homogenous attenuation on CT without areas of hyperattenuation, unilateral involvement of one to two sinuses or bilateral involvement of the sphenoid sinus, and bony erosion localized to the site of extrasinus extension.</p><p class="headingAnchor" id="H346048730"><span class="h2">Eosinophilic mucin rhinosinusitis</span><span class="headingEndMark"> — </span>This is the form of CRS that most closely mimics AFRS. Eosinophilic mucin rhinosinusitis (EMRS) patients have eosinophilic mucin but no detectable fungi in the mucus and sometimes no demonstrable type I allergy to fungus [<a href="#rid6">6,66</a>]. The sinus CT scan in these cases can also show hyperdensities  (<a class="graphic graphic_diagnosticimage graphicRef118030" href="/z/d/graphic/118030.html" rel="external">image 7</a>). However, in EMRS, the warning signs that may be present in AFRS, such as bony expansion and/or bony erosions or facial dysmorphia, are typically not present, and the sinus opacification is usually bilateral and extensive. One study comparing AFRS with EMRS found that T2-weighted MRI signal loss was present in 100 percent of AFRS cases but in only 4.8 percent of EMRS cases [<a href="#rid67">67</a>].</p><p>Although it is possible that some of these cases actually have AFRS, patients with EMRS frequently do not have fungal-specific IgE by skin test or immunoassay and sometimes do not test positive to any allergens. This supports EMRS as a distinct entity, since AFRS patients always have fungal allergy and may also have other inhalant allergies. As many as 50 percent of EMRS cases have Samter's triad of NP, asthma, and aspirin-induced respiratory disease, and many such patients are nonallergic, but this is largely dependent upon how strict clinicians are in diagnosing <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> sensitivity [<a href="#rid66">66</a>]. EMRS is almost always bilateral, whereas AFRS is unilateral in up to one-half of cases. Estimates of the prevalence of EMRS are lacking, but it was reported to be more common than AFRS in one study [<a href="#rid68">68</a>] and in the authors' experience.</p><p class="headingAnchor" id="H346048736"><span class="h2">Unconfirmed or "AFRS candidate" cases</span><span class="headingEndMark"> — </span>These patients have eosinophilic mucin and some but not all of the criteria to fulfill the diagnosis of AFRS. For example, the patient may have no fungi detectable in eosinophilic mucin but have fungal allergy. Alternatively, the patient may have fungi detected in eosinophilic mucin but no evidence for systemic fungal allergy (uncommon). In both instances, the patient can be considered to be an "AFRS candidate" [<a href="#rid69">69</a>]. This categorization also requires examination of specimens obtained during sinus surgery. The major implication of this distinction is in terms of disease classification, as treatment of such patients is likely to be similar or identical to that of an AFRS patient, except perhaps for use of systemic antifungal medication.</p><p class="headingAnchor" id="H346048742"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Based on consensus reports, treatment of AFRS includes both surgical and medical interventions [<a href="#rid70">70,71</a>].</p><p class="headingAnchor" id="H256177685"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>The approach of the authors may be summarized as follows. When the diagnosis of AFRS is entertained and invasive fungal sinusitis is very unlikely, then medical therapy for chronic rhinosinusitis with nasal polyposis (CRS with NP) can be offered as an initial intervention. This is detailed separately. (See  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a>.)</p><p>If that fails, the patient should undergo endoscopic sinus surgery (ESS) to remove accumulated mucin and debris, create adequate drainage, and collect samples of sinus contents for analysis and definitive diagnosis. The authors differ in their preference for a course of presurgical glucocorticoids, although most patients have received these at some point already prior to the diagnosis of AFRS being considered. At the time of surgery, the presence of eosinophilic mucin is confirmed, based on the characteristic appearance of the mucus. The collected mucin as well as sinus tissue is evaluated histologically to determine the presence of eosinophils and fungal elements. Fungal cultures are performed. If there is a concerning clinical picture, it is important that the sinus tissue be examined to rule out invasive fungal sinusitis. Immediately following surgery, oral glucocorticoids are initiated. Glucocorticoid instillations are begun as soon as possible after surgery, with some surgeons beginning instillations on postoperative day 1 and others waiting until the mucosa is healed. The combination of oral and topical glucocorticoids forms the foundation of treatment to suppress local allergic inflammation. After one to three months, we attempt to taper and discontinue oral glucocorticoids, while maintaining the patient on instillations. (See <a class="local">'Systemic glucocorticoids'</a> below and <a class="local">'Topical glucocorticoid instillations'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>The use of antifungal therapy is controversial and is discussed below. (See <a class="local">'Antifungal agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We also encourage patients to undergo a three- to five-year course of subcutaneous injection immunotherapy to address the underlying fungal allergy. (See <a class="local">'Immunotherapy for fungal allergy'</a> below.)</p><p></p><p>Each of these treatment elements is discussed in detail below, with available evidence about efficacy.</p><p class="headingAnchor" id="H346048748"><span class="h2">Endoscopic sinus surgery</span><span class="headingEndMark"> — </span>Endoscopic sinus surgery (ESS) addresses two treatment objectives, in addition to its role in diagnosis (see <a class="local">'Histologic findings'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>The first objective is removal of polyps, inflammatory mucin, and fungal debris. AFRS tends to be recurrent, especially if all affected tissue mucin and polyps are not removed and aeration of affected sinuses is incomplete. It is critical to open the sinuses widely when doing this, as mucin in AFRS is very tenacious, and leaving residual fungal elements or loculated pockets will result in disease recurrence. Surgery with wide marsupialization improves postoperative debridement and delivery of topical glucocorticoids [<a href="#rid72">72,73</a>]. Reported surgical revision rates vary, but a meta-analysis reported that AFRS had higher revision rates of 28.7 percent compared with 18.6 percent for all chronic rhinosinusitis (CRS) with nasal polyposis (NP) patients [<a href="#rid74">74</a>]. A large retrospective review of 536 CRS with NP patients also reported that among AFRS patients, risk factors for revision surgery included younger age (odds ratio [OR] 1.07), male gender (OR 2.60), and previous surgery (OR 2.99) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second objective is reversal of bony expansion into the orbit and brain. Successful surgical and medical management has been shown to reverse proptosis and orbital remodeling in patients with AFRS [<a href="#rid76">76</a>]. Complete bone regeneration in areas of bony erosion has been reported in two-thirds of AFRS cases within 18 months postoperatively [<a href="#rid77">77</a>].</p><p></p><p class="headingAnchor" id="H346048754"><span class="h2">Medical management</span><span class="headingEndMark"> — </span>Medical management consists of systemic and topical glucocorticoids. Other therapies (ie, systemic or topical antifungals, immunotherapy for fungal allergy) are controversial.</p><p class="headingAnchor" id="H346048761"><span class="h3">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>Systemic glucocorticoids are used preoperatively in some cases and postoperatively in all patients.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperatively</strong> – Short courses of systemic glucocorticoids may be given at the surgeon's discretion prior to surgery in some patients with suspected AFRS and extensive polypoid disease, in an effort to "debulk" the polyps, reduce mucosal thickening, and decrease bleeding and edema, thus improving surgical landmarks. However, other surgeons do not favor this, and the best approach is not known. In a series of eight patients with suspected AFRS treated with 1 mg/kg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for 10 days before sinus surgery, there was significant improvement in computed tomography (CT) scan Lund-MacKay scoring and "normalization" of sinus mucosal appearance on imaging performed the day before surgery [<a href="#rid78">78</a>]. Lesser doses of prednisone, such as 40 mg daily for 5 to 10 days, are used by some clinicians (DH's preference). Another study found that prednisone 30 mg daily for 5 days improved visualization of the surgical field during the surgical procedure [<a href="#rid79">79</a>], whereas 15 mg of <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> daily for 10 days preoperatively appeared to have minimal benefit [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperatively</strong> – Systemic glucocorticoids are the mainstay of postoperative management of AFRS and are started immediately following sinus surgery or once the diagnosis is established [<a href="#rid71">71</a>]. In the authors' experience, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> is usually dosed at 0.5 mg/kg daily and tapered over a few weeks to approximately 10 mg daily. Thereafter, the dose is slowly reduced by 1 to 2.5 mg/week to the lowest dose that maintains control of sinus symptoms. The duration of systemic glucocorticoid treatment postoperatively is not well-established. In a retrospective series of 67 postsurgical patients, protracted courses (several months) of oral prednisone delayed the need for repeat surgery [<a href="#rid3">3</a>]. However, in the authors' experience, the use of topical glucocorticoid instillations can reduce the duration of systemic glucocorticoid treatment to one to three months.</p><p></p><p class="bulletIndent1">The benefit of postoperative glucocorticoids was demonstrated in a single, randomized controlled trial, although the doses used in this study were higher than those suggested above. In this trial, 24 subjects with AFRS were randomized either to oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 50 mg/day for six weeks, followed by six additional weeks of tapering prednisone or to placebo [<a href="#rid81">81</a>]. All subjects also received systemic <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> 200 mg/day and glucocorticoid nasal spray for 12 weeks in the postoperative period. At six weeks, complete relief of preoperative symptoms was reported by eight patients receiving prednisone and none of the patients receiving placebo. Nasal endoscopy showed that 8 of 12 patients who had received oral glucocorticoids and 1 patient who had received placebo were free of disease. At 12 weeks, symptom relief was complete in all patients who received prednisone but in only 1 patient who received placebo. However, significant steroid-induced side effects were noted in the prednisone-treated patients, including weight gain, cushingoid features, acne, and glucocorticoid-induced diabetes. Therefore, most expert reports advocate using lower doses and shorter durations of systemic glucocorticoids in the postoperative management of AFRS, such as those described previously.</p><p></p><p class="headingAnchor" id="H346048767"><span class="h3">Topical glucocorticoid instillations</span><span class="headingEndMark"> — </span>As soon as possible after surgery, instillations of topical intranasal glucocorticoids, such as <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>, should be initiated [<a href="#rid82">82</a>]. Some surgeons start these instillations on postoperative day 1, while others wait until the sinus mucosa has healed (usually within two weeks postoperatively), and the best approach has not been studied. Topical glucocorticoid instillations have been highly effective in AFRS patients in the authors' experience, although controlled studies are lacking. After the mucosa has remained normal for 2 to 3 years, we typically attempt to wean patients from their steroid instillations, as AFRS seems to burn itself out as patients reach the age of 30 to 40 years. (See <a class="local">'Prognosis'</a> below.)</p><p>Detailed instructions on how to perform sinus instillations are provided separately. (See  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Intranasal corticosteroids'</a>.)</p><p class="headingAnchor" id="H417368429"><span class="h3">Therapies of uncertain benefit</span><span class="headingEndMark"> — </span>Therapies that are not supported by high quality evidence include immunotherapy for fungal allergy and systemic and topical antifungal treatments.</p><p class="headingAnchor" id="H1043713547"><span class="h4">Immunotherapy for fungal allergy</span><span class="headingEndMark"> — </span>Fungal immunotherapy, using a mixture of fungal allergens based on the results of skin testing or in vitro testing, has been used as an adjunct to surgical and medical therapy in patients with AFRS, and the authors believe this is a rational approach. Although no controlled clinical trials have been performed, fungal immunotherapy has been shown to be safe, with evidence for reduced rates of disease recurrence in some patients [<a href="#rid83">83-87</a>], although the evidence supporting the use of immunotherapy in AFRS is quite limited [<a href="#rid88">88</a>]. The magnitude of effect relative to glucocorticoids is unclear.</p><p>We would suggest subcutaneous immunotherapy (SCIT) instead of oral forms of immunotherapy, as the efficacy of SCIT is better established. We encourage patients to complete a three- to five-year course of SCIT, as this duration of therapy has been shown to provide lasting benefit in some patients. Although the primary purpose of immunotherapy is to address the underlying fungal allergy, we would include any other environmental allergens to which the patient is sensitized as well. (See  <a class="medical medical_review" href="/z/d/html/361.html" rel="external">"Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy"</a>.)</p><p class="headingAnchor" id="H346048773"><span class="h4">Antifungal agents</span><span class="headingEndMark"> — </span>The rationale for antifungal treatment is to stabilize the marked sinus inflammation present in AFRS and reduce long-term use of systemic glucocorticoids.</p><p>Several studies have examined the postoperative use of systemic antifungals for AFRS, although these are limited to open-label trials [<a href="#rid89">89,90</a>] or retrospective case series in adults and children [<a href="#rid91">91,92</a>]. Taken together, these have not shown convincing benefit, and more rigorous studies are needed. There is also limited studies of the use of topical antifungals for treatment of AFRS [<a href="#rid89">89</a>]. Based on the paucity of supportive data, consensus guidelines do not advocate use of oral or topical antifungal agents in AFRS [<a href="#rid71">71,93-95</a>].</p><p>Studies evaluating the effects of systemic antifungal therapies on the postoperative management of AFRS include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective series of 23 patients with AFRS that recurred despite medical and surgical therapy, repeat surgery was followed by <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> 100 mg twice daily for six months [<a href="#rid96">96</a>]. The majority of patients responded to itraconazole treatment, with improvement in symptoms and a reduction of "fungal mucin" on nasal endoscopy, and had a simultaneous reduction in oral steroid use. Furthermore, many of the patients were rendered "disease-free." This study most closely evaluated the manner in which one of the authors (DH) has found oral antifungal therapy to be helpful (ie, in selected patients with recurrent or recalcitrant disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the largest case series of 139 patients, treatment with <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> (average dose 276 mg/day; average duration of therapy 4.3 months) was generally safe, and only 6 patients (4.3 percent) had significant liver enzyme elevation (&gt;2 times the upper limit of normal) [<a href="#rid97">97</a>]. Unfortunately, the data presented in this study did not allow for an assessment of whether itraconazole provided a clinical benefit, although the authors routinely tapered and discontinued patients' <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, suggesting that the incorporation of itraconazole into the postoperative management may have facilitated this.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other studies have incorporated <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> in the postsurgical management of AFRS in conjunction with systemic glucocorticoid treatment [<a href="#rid81">81,97,98</a>].</p><p></p><p>One study preliminarily evaluated medical therapy for AFRS. <strong>Preoperative</strong> treatment with oral <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> was evaluated in a prospective study of 27 patients compared with 25 matched control patients, all of whom were considered at study entry to have AFRS. A concern about this study is that it is unclear how patients were suspected of having AFRS prior to sinus surgery [<a href="#rid99">99</a>]. Further evaluation of this approach is needed before it can be recommended as a treatment option.</p><p class="headingAnchor" id="H346048785"><span class="h3">Investigational therapies</span><span class="headingEndMark"> — </span>Investigational therapies include biologics:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a>, an anti-IL-4/IL-13 monoclonal antibody, is approved by the US Food and Drug Administration for treatment of refractory nasal polyposis (see  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Anti-IL-4RA (dupilumab)'</a> and  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Biologic therapies'</a>). It has not yet been studied in controlled clinical trials for AFRS, but there are case reports of its use [<a href="#rid100">100,101</a>]. Until further studies are done, the criteria for use of biologics for AFRS should follow established guidelines for their use for refractory nasal polyposis. In cases where the diagnosis of AFRS is suspected and there is bony expansion and/or bony erosions, extension of sinus disease to extrasinus areas (such as the orbit, skin, or brain), double or reduced vision, proptosis, dramatic periorbital edema, ophthalmoplegia, facial dysmorphia, other focal neurologic signs, severe headache, meningeal signs, or significant or recurrent epistaxis or unilateral sinus disease, we recommend adhering to the standard approach (see <a class="local">'Our approach'</a> above). This includes performing endoscopic sinus surgery (ESS) to remove accumulated mucin and debris, create adequate drainage, and collect samples of sinus contents for analysis and definitive diagnosis. Following this, if the patient has a recurrence of polyposis, use of a biologic agent might be an appropriate treatment option. Ongoing clinical trials for patients with AFRS can be found at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=101017" target="_blank">clinicaltrials.gov</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">Omalizumab</a>, an anti-IgE monoclonal antibody, was found to be beneficial for AFRS in a case report and in a retrospective chart review of seven AFRS patients who also had moderate or severe asthma [<a href="#rid102">102,103</a>]. A single dose of omalizumab was found to be superior to treatment with an intranasal corticosteroid nasal spray (100 mcg twice daily) over the first six months following sinus surgery in a small single-blinded clinical trial [<a href="#rid104">104</a>].</p><p></p><p class="headingAnchor" id="H256177864"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>AFRS nearly always recurs if patients are not treated with postsurgical glucocorticoids or are not compliant with therapy. For those who are treated appropriately and are consistent with topical therapies, symptoms can usually be controlled to a degree that is satisfactory to the patient. Most can eventually discontinue therapy after a few years without the problem recurring. The disorder seems to be most aggressive in young adults and becomes easier to control as the patient enters his/her 30s or 40s.</p><p class="headingAnchor" id="H2557115678"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110441.html" rel="external">"Society guideline links: Chronic rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H346048791"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/86637.html" rel="external">"Patient education: Chronic sinusitis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86630.html" rel="external">"Patient education: How to rinse out your nose with salt water (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/378.html" rel="external">"Patient education: Chronic rhinosinusitis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H346048797"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis</strong> – Allergic fungal rhinosinusitis (AFRS) is a distinct subtype of chronic rhinosinusitis (CRS), which accounts for 5 to 10 percent of CRS cases. It is important to recognize, as the approach to diagnosis and treatment of AFRS always involves a combination of surgical and medical management. AFRS arises as a result of localized polypoid inflammation in response to noninvasive fungal growth in areas of compromised mucus drainage. The affected sinuses become packed with eosinophilic mucin, which is a thick, tenacious eosinophilic secretion. This mucin contains fungal hyphae, but there is no fungal invasion of the underlying mucosa or bone. Affected patients are immunocompetent and have demonstrable allergy to fungi. (See <a class="local">'Definition'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Signs and symptoms</strong> – The cardinal symptoms of AFRS are the same as those of CRS with nasal polyposis (CRS with NP), namely mucopurulent drainage, nasal obstruction, facial pain and/or pressure, and decreased olfaction. Some patients with AFRS present with proptosis or gross facial dysmorphia due to local pressure effects on the bone, although even with severe disease, symptoms may be relatively mild, as the condition often develops slowly over time. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The majority of cases of AFRS have been reported in the southern United States, specifically along the Mississippi River basin, although the disorder is reported worldwide. It disproportionately affects younger patients, African Americans, and patients of lower socioeconomic status for reasons that are not entirely understood. (See <a class="local">'Epidemiology and possible risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The evaluation of AFRS involves a clinical history and objective documentation of mucosal disease with either rhinoscopy or nasal endoscopy with decongestion or with sinus computed tomography (CT) imaging. AFRS has characteristic findings on CT. Allergy evaluation is needed to establish the presence of fungal allergy, and immunologic evaluation should exclude diabetes or immune defects. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Endoscopic sinus surgery (ESS) is indicated in all patients with suspected AFRS to establish the presence of eosinophilic mucin and obtain samples for histologic evaluation and fungal culture, which are required for diagnosis. Diagnostic criteria for AFRS have been proposed. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis includes several entities, but acute and chronic invasive fungal sinusitis are the most critical to exclude. In invasive forms of fungal sinusitis, hyphae can be seen histologically to invade the sinus mucosa, submucosa, blood vessels, or bone. Acute invasive fungal sinusitis typically occurs only in patients with diabetes mellitus or immunodeficiency and can be life-threatening. (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/2452.html" rel="external">"Fungal rhinosinusitis", section on 'Invasive fungal sinusitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The primary components of AFRS management are ESS, in combination with systemic and/or topical glucocorticoids. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ESS is indicated in all patients with suspected AFRS to remove inflammatory mucin, fungal debris, and nasal polyps and to relieve any pressure on bones of the orbit and skull. We suggest wide marsupialization of the affected sinuses to improve postoperative debridement and delivery of topical medications, rather than more conservative procedures (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Endoscopic sinus surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral glucocorticoids are sometimes given preoperatively to improve visualization of the surgical field, although this practice is variable and is usually left to the discretion of the surgeon. In contrast, we recommend that all patients with AFRS receive systemic glucocorticoids postoperatively (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). A common regimen is oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (0.5 mg/kg daily), tapered over a few weeks to approximately 10 mg daily. Thereafter, the dose is slowly reduced by 1 to 2.5 mg per week to the lowest dose that maintains control of sinus symptoms. The usual duration of systemic treatment is one to three months. (See <a class="local">'Systemic glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We also suggest instillations of topical intranasal glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). These should be initiated as soon as possible after surgery and continued indefinitely, at least for the next few years. (See <a class="local">'Topical glucocorticoid instillations'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapies of uncertain benefit</strong> – Therapies of uncertain efficacy include subcutaneous immunotherapy (SCIT) for fungal allergy, systemic antifungal agents, and biologic agents. (See <a class="local">'Therapies of uncertain benefit'</a> above and <a class="local">'Investigational therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – AFRS nearly always recurs if patients are not treated with postsurgical glucocorticoids or are not compliant with therapy. For those who are treated appropriately and are consistent with ongoing instillations of glucocorticoids, symptoms can usually be controlled to a degree that is satisfactory to the patient. Most can eventually discontinue therapy after a few years without the problem recurring. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1091515275"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Daniel L Hamilos, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bush RK, Portnoy JM, Saxon A, et al. The medical effects of mold exposure. J Allergy Clin Immunol 2006; 117:326.</a></li><li><a class="nounderline abstract_t">Luong A, Marple BF. Allergic fungal rhinosinusitis. Curr Allergy Asthma Rep 2004; 4:465.</a></li><li><a class="nounderline abstract_t">Schubert MS, Goetz DW. Evaluation and treatment of allergic fungal sinusitis. II. Treatment and follow-up. J Allergy Clin Immunol 1998; 102:395.</a></li><li><a class="nounderline abstract_t">Hamilos DL, Lund VJ. Etiology of chronic rhinosinusitis: the role of fungus. Ann Otol Rhinol Laryngol Suppl 2004; 193:27.</a></li><li><a class="nounderline abstract_t">Luong A, Davis LS, Marple BF. Peripheral blood mononuclear cells from allergic fungal rhinosinusitis adults express a Th2 cytokine response to fungal antigens. Am J Rhinol Allergy 2009; 23:281.</a></li><li><a class="nounderline abstract_t">Pant H, Kette FE, Smith WB, et al. Fungal-specific humoral response in eosinophilic mucus chronic rhinosinusitis. Laryngoscope 2005; 115:601.</a></li><li><a class="nounderline abstract_t">Manning SC, Schaefer SD, Close LG, Vuitch F. Culture-positive allergic fungal sinusitis. Arch Otolaryngol Head Neck Surg 1991; 117:174.</a></li><li><a class="nounderline abstract_t">Torres C, Ro JY, el-Naggar AK, et al. Allergic fungal sinusitis: a clinicopathologic study of 16 cases. Hum Pathol 1996; 27:793.</a></li><li><a class="nounderline abstract_t">Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 1999; 74:877.</a></li><li><a class="nounderline abstract_t">Cleland EJ, Bassiouni A, Boase S, et al. The fungal microbiome in chronic rhinosinusitis: richness, diversity, postoperative changes and patient outcomes. Int Forum Allergy Rhinol 2014; 4:259.</a></li><li><a class="nounderline abstract_t">Safirstein BH. Allergic bronchopulmonary aspergillosis with obstruction of the upper respiratory tract. Chest 1976; 70:788.</a></li><li><a class="nounderline abstract_t">Al-Dousary SH. Allergic fungal sinusitis: radiological and microbiological features of 59 cases. Ann Saudi Med 2008; 28:17.</a></li><li><a class="nounderline abstract_t">Revankar SG, Sutton DA. Melanized fungi in human disease. Clin Microbiol Rev 2010; 23:884.</a></li><li class="breakAll">Dematiaceous fungi. Mount Sinai Hospital. http://microbiology.mtsinai.on.ca/mig/defungi/index.shtml (Accessed on June 23, 2015).</li><li><a class="nounderline abstract_t">Kimura M, McGinnis MR. Fontana-Masson--stained tissue from culture-proven mycoses. Arch Pathol Lab Med 1998; 122:1107.</a></li><li><a class="nounderline abstract_t">Shin SH, Ponikau JU, Sherris DA, et al. Chronic rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi. J Allergy Clin Immunol 2004; 114:1369.</a></li><li><a class="nounderline abstract_t">Braun H, Stammberger H, Buzina W, et al. [Incidence and detection of fungi and eosinophilic granulocytes in chronic rhinosinusitis]. Laryngorhinootologie 2003; 82:330.</a></li><li><a class="nounderline abstract_t">Braun H, Buzina W, Freudenschuss K, et al. 'Eosinophilic fungal rhinosinusitis': a common disorder in Europe? Laryngoscope 2003; 113:264.</a></li><li><a class="nounderline abstract_t">Orlandi RR, Marple BF. Fungus and chronic rhinosinusitis: weighing the evidence. Otolaryngol Head Neck Surg 2010; 143:611.</a></li><li><a class="nounderline abstract_t">Okano M, Fujiwara T, Haruna T, et al. Role of fungal antigens in eosinophilia-associated cellular responses in nasal polyps: a comparison with enterotoxin. Clin Exp Allergy 2011; 41:171.</a></li><li><a class="nounderline abstract_t">Orlandi RR, Marple BF, Georgelas A, et al. Immunologic response to fungus is not universally associated with rhinosinusitis. Otolaryngol Head Neck Surg 2009; 141:750.</a></li><li><a class="nounderline abstract_t">Clark DW, Wenaas A, Luong A, et al. Staphylococcus aureus prevalence in allergic fungal rhinosinusitis vs other subsets of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 2013; 3:89.</a></li><li><a class="nounderline abstract_t">Dutre T, Al Dousary S, Zhang N, Bachert C. Allergic fungal rhinosinusitis-more than a fungal disease? J Allergy Clin Immunol 2013; 132:487.</a></li><li><a class="nounderline abstract_t">AlQahtani A, Alim B, Almudhaibery F, et al. The Impact of Climatic, Socioeconomic, and Geographic Factors on the Prevalence of Allergic Fungal Rhinosinusitis: A Worldwide Ecological Study. Am J Rhinol Allergy 2022; 36:423.</a></li><li><a class="nounderline abstract_t">Ferguson BJ, Barnes L, Bernstein JM, et al. Geographic variation in allergic fungal rhinosinusitis. Otolaryngol Clin North Am 2000; 33:441.</a></li><li><a class="nounderline abstract_t">Wise SK, Ghegan MD, Gorham E, Schlosser RJ. Socioeconomic factors in the diagnosis of allergic fungal rhinosinusitis. Otolaryngol Head Neck Surg 2008; 138:38.</a></li><li><a class="nounderline abstract_t">Lu-Myers Y, Deal AM, Miller JD, et al. Comparison of Socioeconomic and Demographic Factors in Patients with Chronic Rhinosinusitis and Allergic Fungal Rhinosinusitis. Otolaryngol Head Neck Surg 2015; 153:137.</a></li><li><a class="nounderline abstract_t">Rowan NR, Storck KA, Schlosser RJ, Soler ZM. The Role of Home Fungal Exposure in Allergic Fungal Rhinosinusitis. Am J Rhinol Allergy 2020; 34:784.</a></li><li><a class="nounderline abstract_t">Orlandi RR, Kingdom TT, Hwang PH, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol 2016; 6 Suppl 1:S22.</a></li><li><a class="nounderline abstract_t">Muntz HR. Allergic fungal sinusitis in children. Otolaryngol Clin North Am 1996; 29:185.</a></li><li><a class="nounderline abstract_t">Mafee MF. Imaging of paranasal sinuses and rhinosinusitis. Clin Allergy Immunol 2007; 20:185.</a></li><li><a class="nounderline abstract_t">Manning SC, Mabry RL, Schaefer SD, Close LG. Evidence of IgE-mediated hypersensitivity in allergic fungal sinusitis. Laryngoscope 1993; 103:717.</a></li><li><a class="nounderline abstract_t">Manning SC, Vuitch F, Weinberg AG, Brown OE. Allergic aspergillosis: a newly recognized form of sinusitis in the pediatric population. Laryngoscope 1989; 99:681.</a></li><li><a class="nounderline abstract_t">Marple BF, Gibbs SR, Newcomer MT, Mabry RL. Allergic fungal sinusitis-induced visual loss. Am J Rhinol 1999; 13:191.</a></li><li><a class="nounderline abstract_t">Soler ZM, Hyer JM, Ramakrishnan V, et al. Identification of chronic rhinosinusitis phenotypes using cluster analysis. Int Forum Allergy Rhinol 2015; 5:399.</a></li><li><a class="nounderline abstract_t">Smith TL, Mendolia-Loffredo S, Loehrl TA, et al. Predictive factors and outcomes in endoscopic sinus surgery for chronic rhinosinusitis. Laryngoscope 2005; 115:2199.</a></li><li><a class="nounderline abstract_t">Gliklich RE, Metson R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg 1995; 113:104.</a></li><li><a class="nounderline abstract_t">Hutcheson PS, Schubert MS, Slavin RG. Distinctions between allergic fungal rhinosinusitis and chronic rhinosinusitis. Am J Rhinol Allergy 2010; 24:405.</a></li><li><a class="nounderline abstract_t">Bent JP 3rd, Kuhn FA. Diagnosis of allergic fungal sinusitis. Otolaryngol Head Neck Surg 1994; 111:580.</a></li><li><a class="nounderline abstract_t">Mukherji SK, Figueroa RE, Ginsberg LE, et al. Allergic fungal sinusitis: CT findings. Radiology 1998; 207:417.</a></li><li><a class="nounderline abstract_t">Nussenbaum B, Marple BF, Schwade ND. Characteristics of bony erosion in allergic fungal rhinosinusitis. Otolaryngol Head Neck Surg 2001; 124:150.</a></li><li><a class="nounderline abstract_t">Michaels L, Lloyd G, Phelps P. Origin and spread of allergic fungal disease of the nose and paranasal sinuses. Clin Otolaryngol Allied Sci 2000; 25:518.</a></li><li><a class="nounderline abstract_t">Bozeman S, deShazo R, Stringer S, Wright L. Complications of allergic fungal sinusitis. Am J Med 2011; 124:359.</a></li><li><a class="nounderline abstract_t">Ghegan MD, Lee FS, Schlosser RJ. Incidence of skull base and orbital erosion in allergic fungal rhinosinusitis (AFRS) and non-AFRS. Otolaryngol Head Neck Surg 2006; 134:592.</a></li><li><a class="nounderline abstract_t">McClay JE, Marple B, Kapadia L, et al. Clinical presentation of allergic fungal sinusitis in children. Laryngoscope 2002; 112:565.</a></li><li><a class="nounderline abstract_t">Marfani MS, Jawaid MA, Shaikh SM, Thaheem K. Allergic fungal rhinosinusitis with skull base and orbital erosion. J Laryngol Otol 2010; 124:161.</a></li><li><a class="nounderline abstract_t">Ghegan MD, Wise SK, Gorham E, Schlosser RJ. Socioeconomic factors in allergic fungal rhinosinusitis with bone erosion. Am J Rhinol 2007; 21:560.</a></li><li><a class="nounderline abstract_t">Zinreich SJ, Kennedy DW, Malat J, et al. Fungal sinusitis: diagnosis with CT and MR imaging. Radiology 1988; 169:439.</a></li><li><a class="nounderline abstract_t">Kaschke O, Rumor D, Jautzke G, et al. [Investigations on allergic fungal genesis of chronic rhinosinusitis]. Laryngorhinootologie 2002; 81:629.</a></li><li><a class="nounderline abstract_t">Schubert MS. Fungal rhinosinusitis: diagnosis and therapy. Curr Allergy Asthma Rep 2001; 1:268.</a></li><li><a class="nounderline abstract_t">Katzenstein AL, Sale SR, Greenberger PA. Pathologic findings in allergic aspergillus sinusitis. A newly recognized form of sinusitis. Am J Surg Pathol 1983; 7:439.</a></li><li><a class="nounderline abstract_t">Hamilos DL. Chronic rhinosinusitis: epidemiology and medical management. J Allergy Clin Immunol 2011; 128:693.</a></li><li><a class="nounderline abstract_t">Guo C, Ghadersohi S, Kephart GM, et al. Improving the detection of fungi in eosinophilic mucin: seeing what we could not see before. Otolaryngol Head Neck Surg 2012; 147:943.</a></li><li><a class="nounderline abstract_t">Javer AR, Genoway KA, Gervais M, et al. Fungal cultures in patients with allergic fungal rhinosinusitis: improving the recovery of potential fungal pathogens in the Canadian laboratory. J Otolaryngol 2007; 36:1.</a></li><li><a class="nounderline abstract_t">Lebowitz RA, Waltzman MN, Jacobs JB, et al. Isolation of fungi by standard laboratory methods in patients with chronic rhinosinusitis. Laryngoscope 2002; 112:2189.</a></li><li><a class="nounderline abstract_t">Montone KT, Livolsi VA, Lanza DC, et al. Rapid In-situ hybridization for dematiaceous fungi using a broad-spectrum oligonucleotide DNA probe. Diagn Mol Pathol 2011; 20:180.</a></li><li><a class="nounderline abstract_t">deShazo RD, Swain RE. Diagnostic criteria for allergic fungal sinusitis. J Allergy Clin Immunol 1995; 96:24.</a></li><li><a class="nounderline abstract_t">Hamilos DL. Allergic fungal rhinitis and rhinosinusitis. Proc Am Thorac Soc 2010; 7:245.</a></li><li><a class="nounderline abstract_t">Horner WE, Helbling A, Salvaggio JE, Lehrer SB. Fungal allergens. Clin Microbiol Rev 1995; 8:161.</a></li><li><a class="nounderline abstract_t">Morpeth JF, Rupp NT, Dolen WK, et al. Fungal sinusitis: an update. Ann Allergy Asthma Immunol 1996; 76:128.</a></li><li><a class="nounderline abstract_t">deShazo RD, O'Brien M, Chapin K, et al. A new classification and diagnostic criteria for invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg 1997; 123:1181.</a></li><li><a class="nounderline abstract_t">Blitzer A, Lawson W, Meyers BR, Biller HF. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope 1980; 90:635.</a></li><li><a class="nounderline abstract_t">Chakrabarti A, Sharma SC, Chandler J. Epidemiology and pathogenesis of paranasal sinus mycoses. Otolaryngol Head Neck Surg 1992; 107:745.</a></li><li><a class="nounderline abstract_t">Washburn RG, Kennedy DW, Begley MG, et al. Chronic fungal sinusitis in apparently normal hosts. Medicine (Baltimore) 1988; 67:231.</a></li><li><a class="nounderline abstract_t">Reddy CE, Gupta AK, Singh P, Mann SB. Imaging of granulomatous and chronic invasive fungal sinusitis: comparison with allergic fungal sinusitis. Otolaryngol Head Neck Surg 2010; 143:294.</a></li><li><a class="nounderline abstract_t">Ferguson BJ. Eosinophilic mucin rhinosinusitis: a distinct clinicopathological entity. Laryngoscope 2000; 110:799.</a></li><li><a class="nounderline abstract_t">Meng Y, Zhang L, Piao Y, et al. The use of magnetic resonance imaging in differential diagnosis of allergic fungal sinusitis and eosinophilic mucin rhinosinusitis. J Thorac Dis 2019; 11:3569.</a></li><li><a class="nounderline abstract_t">Uri N, Ronen O, Marshak T, et al. Allergic fungal sinusitis and eosinophilic mucin rhinosinusitis: diagnostic criteria. J Laryngol Otol 2013; 127:867.</a></li><li><a class="nounderline abstract_t">Schubert MS. Allergic fungal sinusitis. Clin Rev Allergy Immunol 2006; 30:205.</a></li><li><a class="nounderline abstract_t">Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50:1.</a></li><li><a class="nounderline abstract_t">Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol 2014; 113:347.</a></li><li><a class="nounderline abstract_t">Thomas WW 3rd, Harvey RJ, Rudmik L, et al. Distribution of topical agents to the paranasal sinuses: an evidence-based review with recommendations. Int Forum Allergy Rhinol 2013; 3:691.</a></li><li><a class="nounderline abstract_t">Huchton DM. Allergic fungal sinusitis: an otorhinolaryngologic perspective. Allergy Asthma Proc 2003; 24:307.</a></li><li><a class="nounderline abstract_t">Loftus CA, Soler ZM, Koochakzadeh S, et al. Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. Int Forum Allergy Rhinol 2020; 10:199.</a></li><li><a class="nounderline abstract_t">Loftus CA, Soler ZM, Desiato VM, et al. Factors impacting revision surgery in patients with chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol 2020; 10:289.</a></li><li><a class="nounderline abstract_t">Stonebraker AC, Schlosser RJ. Orbital volumetric analysis of allergic fungal sinusitis patients with proptosis before and after endoscopic sinus surgery. Am J Rhinol 2005; 19:302.</a></li><li><a class="nounderline abstract_t">Alarifi I, Al-Dousary S, Bin Hazza'a A, Sumaily I. Bone Regeneration in Allergic Fungal Rhinosinusitis: Post-treatment Image Follow Up. Cureus 2019; 11:e6502.</a></li><li><a class="nounderline abstract_t">Landsberg R, Segev Y, DeRowe A, et al. Systemic corticosteroids for allergic fungal rhinosinusitis and chronic rhinosinusitis with nasal polyposis: a comparative study. Otolaryngol Head Neck Surg 2007; 136:252.</a></li><li><a class="nounderline abstract_t">Sieskiewicz A, Olszewska E, Rogowski M, Grycz E. Preoperative corticosteroid oral therapy and intraoperative bleeding during functional endoscopic sinus surgery in patients with severe nasal polyposis: a preliminary investigation. Ann Otol Rhinol Laryngol 2006; 115:490.</a></li><li><a class="nounderline abstract_t">Hong SJ, Lee JK, Lee HS, et al. Availability of preoperative systemic steroids on endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Yonsei Med J 2014; 55:1683.</a></li><li><a class="nounderline abstract_t">Rupa V, Jacob M, Mathews MS, Seshadri MS. A prospective, randomised, placebo-controlled trial of postoperative oral steroid in allergic fungal sinusitis. Eur Arch Otorhinolaryngol 2010; 267:233.</a></li><li><a class="nounderline abstract_t">Gan EC, Thamboo A, Rudmik L, et al. Medical management of allergic fungal rhinosinusitis following endoscopic sinus surgery: an evidence-based review and recommendations. Int Forum Allergy Rhinol 2014; 4:702.</a></li><li><a class="nounderline abstract_t">Bassichis BA, Marple BF, Mabry RL, et al. Use of immunotherapy in previously treated patients with allergic fungal sinusitis. Otolaryngol Head Neck Surg 2001; 125:487.</a></li><li><a class="nounderline abstract_t">Greenhaw B, deShazo RD, Arnold J, Wright L. Fungal immunotherapy in patients with allergic fungal sinusitis. Ann Allergy Asthma Immunol 2011; 107:432.</a></li><li><a class="nounderline abstract_t">Hall AG, deShazo RD. Immunotherapy for allergic fungal sinusitis. Curr Opin Allergy Clin Immunol 2012; 12:629.</a></li><li><a class="nounderline abstract_t">Marple B, Newcomer M, Schwade N, Mabry R. Natural history of allergic fungal rhinosinusitis: a 4- to 10-year follow-up. Otolaryngol Head Neck Surg 2002; 127:361.</a></li><li><a class="nounderline abstract_t">Doellman MS, Dion GR, Weitzel EK, Reyes EG. Immunotherapy in allergic fungal sinusitis: The controversy continues. A recent review of literature. Allergy Rhinol (Providence) 2013; 4:e32.</a></li><li><a class="nounderline abstract_t">DeYoung K, Wentzel JL, Schlosser RJ, et al. Systematic review of immunotherapy for chronic rhinosinusitis. Am J Rhinol Allergy 2014; 28:145.</a></li><li><a class="nounderline abstract_t">Khalil Y, Tharwat A, Abdou AG, et al. The role of antifungal therapy in the prevention of recurrent allergic fungal rhinosinusitis after functional endoscopic sinus surgery: a randomized, controlled study. Ear Nose Throat J 2011; 90:E1.</a></li><li><a class="nounderline abstract_t">Chan KO, Genoway KA, Javer AR. Effectiveness of itraconazole in the management of refractory allergic fungal rhinosinusitis. J Otolaryngol Head Neck Surg 2008; 37:870.</a></li><li><a class="nounderline abstract_t">Kinsella JB, Bradfield JJ, Gourley WK, et al. Allergic fungal sinusitis. Clin Otolaryngol Allied Sci 1996; 21:389.</a></li><li><a class="nounderline abstract_t">Kupferberg SB, Bent JP. Allergic fungal sinusitis in the pediatric population. Arch Otolaryngol Head Neck Surg 1996; 122:1381.</a></li><li><a class="nounderline abstract_t">Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Clin Exp Allergy 2008; 38:260.</a></li><li><a class="nounderline abstract_t">Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015; 152:S1.</a></li><li><a class="nounderline abstract_t">Fokkens W, Lund V, Bachert C, et al. EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy 2005; 60:583.</a></li><li><a class="nounderline abstract_t">Seiberling K, Wormald PJ. The role of itraconazole in recalcitrant fungal sinusitis. Am J Rhinol Allergy 2009; 23:303.</a></li><li><a class="nounderline abstract_t">Rains BM 3rd, Mineck CW. Treatment of allergic fungal sinusitis with high-dose itraconazole. Am J Rhinol 2003; 17:1.</a></li><li><a class="nounderline abstract_t">Kupferberg SB, Bent JP 3rd, Kuhn FA. Prognosis for allergic fungal sinusitis. Otolaryngol Head Neck Surg 1997; 117:35.</a></li><li><a class="nounderline abstract_t">Patro SK, Verma RK, Panda NK, et al. Efficacy of preoperative itraconazole in allergic fungal rhinosinusitis. Am J Rhinol Allergy 2015; 29:299.</a></li><li><a class="nounderline abstract_t">Bulkhi AA, Mirza AA, Aburiziza AJ, Marglani OA. Dupilumab: An emerging therapy in allergic fungal rhinosinusitis. World Allergy Organ J 2022; 15:100638.</a></li><li><a class="nounderline abstract_t">Mujahed RA, Marglani OA, Maksood LS, Felemban TA. Successful Use of Dupilumab as a Salvage Therapy for Recalcitrant Allergic Fungal Rhinosinusitis: A Case Report. Cureus 2022; 14:e23104.</a></li><li><a class="nounderline abstract_t">Evans MO 2nd, Coop CA. Novel treatment of allergic fungal sinusitis using omalizumab. Allergy Rhinol (Providence) 2014; 5:172.</a></li><li><a class="nounderline abstract_t">Gan EC, Habib AR, Rajwani A, Javer AR. Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthma. Am J Otolaryngol 2015; 36:672.</a></li><li><a class="nounderline abstract_t">Mostafa BE, Fadel M, Mohammed MA, et al. Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis. Eur Arch Otorhinolaryngol 2020; 277:121.</a></li></ol></div><div id="topicVersionRevision">Topic 101017 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16514772" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The medical effects of mold exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15462713" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Allergic fungal rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768579" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evaluation and treatment of allergic fungal sinusitis. II. Treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15174758" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Etiology of chronic rhinosinusitis: the role of fungus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19490802" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Peripheral blood mononuclear cells from allergic fungal rhinosinusitis adults express a Th2 cytokine response to fungal antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15805867" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fungal-specific humoral response in eosinophilic mucus chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1991058" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Culture-positive allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8760012" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Allergic fungal sinusitis: a clinicopathologic study of 16 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10488788" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The diagnosis and incidence of allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500871" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The fungal microbiome in chronic rhinosinusitis: richness, diversity, postoperative changes and patient outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1001063" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Allergic bronchopulmonary aspergillosis with obstruction of the upper respiratory tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299641" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Allergic fungal sinusitis: radiological and microbiological features of 59 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20930077" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Melanized fungi in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20930077" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Melanized fungi in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9870861" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fontana-Masson--stained tissue from culture-proven mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15577837" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chronic rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12800078" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : [Incidence and detection of fungi and eosinophilic granulocytes in chronic rhinosinusitis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12567080" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 'Eosinophilic fungal rhinosinusitis': a common disorder in Europe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20974327" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fungus and chronic rhinosinusitis: weighing the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21039976" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Role of fungal antigens in eosinophilia-associated cellular responses in nasal polyps: a comparison with enterotoxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19932849" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunologic response to fungus is not universally associated with rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23038642" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Staphylococcus aureus prevalence in allergic fungal rhinosinusitis vs other subsets of chronic rhinosinusitis with nasal polyps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23608727" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Allergic fungal rhinosinusitis-more than a fungal disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35187957" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The Impact of Climatic, Socioeconomic, and Geographic Factors on the Prevalence of Allergic Fungal Rhinosinusitis: A Worldwide Ecological Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10736417" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Geographic variation in allergic fungal rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164991" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Socioeconomic factors in the diagnosis of allergic fungal rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25917670" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of Socioeconomic and Demographic Factors in Patients with Chronic Rhinosinusitis and Allergic Fungal Rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32539434" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The Role of Home Fungal Exposure in Allergic Fungal Rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26889651" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : International Consensus Statement on Allergy and Rhinology: Rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8834281" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Allergic fungal sinusitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17534053" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Imaging of paranasal sinuses and rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8341095" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evidence of IgE-mediated hypersensitivity in allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2747391" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Allergic aspergillosis: a newly recognized form of sinusitis in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392237" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Allergic fungal sinusitis-induced visual loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25694390" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Identification of chronic rhinosinusitis phenotypes using cluster analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369166" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Predictive factors and outcomes in endoscopic sinus surgery for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7603703" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The health impact of chronic sinusitis in patients seeking otolaryngologic care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21144218" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Distinctions between allergic fungal rhinosinusitis and chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7970796" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Diagnosis of allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9577490" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Allergic fungal sinusitis: CT findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11226947" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Characteristics of bony erosion in allergic fungal rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122292" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Origin and spread of allergic fungal disease of the nose and paranasal sinuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21435427" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Complications of allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16564378" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Incidence of skull base and orbital erosion in allergic fungal rhinosinusitis (AFRS) and non-AFRS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12148872" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical presentation of allergic fungal sinusitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19954557" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Allergic fungal rhinosinusitis with skull base and orbital erosion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17999790" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Socioeconomic factors in allergic fungal rhinosinusitis with bone erosion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3174990" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Fungal sinusitis: diagnosis with CT and MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12357410" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : [Investigations on allergic fungal genesis of chronic rhinosinusitis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11892045" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fungal rhinosinusitis: diagnosis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6614309" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pathologic findings in allergic aspergillus sinusitis. A newly recognized form of sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21890184" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chronic rhinosinusitis: epidemiology and medical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22687329" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Improving the detection of fungi in eosinophilic mucin: seeing what we could not see before.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17376343" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fungal cultures in patients with allergic fungal rhinosinusitis: improving the recovery of potential fungal pathogens in the Canadian laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12461339" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Isolation of fungi by standard laboratory methods in patients with chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21817900" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rapid In-situ hybridization for dematiaceous fungi using a broad-spectrum oligonucleotide DNA probe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7622760" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Diagnostic criteria for allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463255" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Allergic fungal rhinitis and rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7621398" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fungal allergens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8595530" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fungal sinusitis: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366697" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A new classification and diagnostic criteria for invasive fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7359982" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Patient survival factors in paranasal sinus mucormycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1470451" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Epidemiology and pathogenesis of paranasal sinus mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3393078" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Chronic fungal sinusitis in apparently normal hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647138" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Imaging of granulomatous and chronic invasive fungal sinusitis: comparison with allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807359" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Eosinophilic mucin rhinosinusitis: a distinct clinicopathological entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31559063" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The use of magnetic resonance imaging in differential diagnosis of allergic fungal sinusitis and eosinophilic mucin rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23941690" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Allergic fungal sinusitis and eosinophilic mucin rhinosinusitis: diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16785591" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22469599" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25256029" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diagnosis and management of rhinosinusitis: a practice parameter update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23729216" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Distribution of topical agents to the paranasal sinuses: an evidence-based review with recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14619329" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Allergic fungal sinusitis: an otorhinolaryngologic perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31752051" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31943850" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Factors impacting revision surgery in patients with chronic rhinosinusitis with nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16011139" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Orbital volumetric analysis of allergic fungal sinusitis patients with proptosis before and after endoscopic sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32025423" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Bone Regeneration in Allergic Fungal Rhinosinusitis: Post-treatment Image Follow Up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17275549" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Systemic corticosteroids for allergic fungal rhinosinusitis and chronic rhinosinusitis with nasal polyposis: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16900802" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Preoperative corticosteroid oral therapy and intraoperative bleeding during functional endoscopic sinus surgery in patients with severe nasal polyposis: a preliminary investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25323909" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Availability of preoperative systemic steroids on endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19714349" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A prospective, randomised, placebo-controlled trial of postoperative oral steroid in allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25044729" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Medical management of allergic fungal rhinosinusitis following endoscopic sinus surgery: an evidence-based review and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11700447" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Use of immunotherapy in previously treated patients with allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22018615" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Fungal immunotherapy in patients with allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23095911" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Immunotherapy for allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12447228" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Natural history of allergic fungal rhinosinusitis: a 4- to 10-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23772324" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Immunotherapy in allergic fungal sinusitis: The controversy continues. A recent review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24717953" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Systematic review of immunotherapy for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21853425" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The role of antifungal therapy in the prevention of recurrent allergic fungal rhinosinusitis after functional endoscopic sinus surgery: a randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19128719" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effectiveness of itraconazole in the management of refractory allergic fungal rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8932939" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8956755" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Allergic fungal sinusitis in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18167126" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : BSACI guidelines for the management of rhinosinusitis and nasal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832968" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Clinical practice guideline (update): adult sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15813802" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : EAACI position paper on rhinosinusitis and nasal polyps executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19490806" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The role of itraconazole in recalcitrant fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12703478" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Treatment of allergic fungal sinusitis with high-dose itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9230320" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Prognosis for allergic fungal sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26163250" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Efficacy of preoperative itraconazole in allergic fungal rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35497650" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Dupilumab: An emerging therapy in allergic fungal rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35464536" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Successful Use of Dupilumab as a Salvage Therapy for Recalcitrant Allergic Fungal Rhinosinusitis: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25565055" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Novel treatment of allergic fungal sinusitis using omalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26117492" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31552526" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
